Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M501306200 on June 9, 2005

J. Biol. Chem., Vol. 280, Issue 34, 30018-30024, August 26, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/34/30018    most recent
M501306200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stojanovic, M.
Right arrow Articles by Shore, G. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stojanovic, M.
Right arrow Articles by Shore, G. C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

BAP31 and Its Caspase Cleavage Product Regulate Cell Surface Expression of Tetraspanins and Integrin-mediated Cell Survival*

Marina Stojanovic{ddagger}, Marc Germain{ddagger}§, Mai Nguyen{ddagger}, and Gordon C. Shore{ddagger}||

From the {ddagger}Department of Biochemistry and McGill Cancer Center, McIntyre Medical Sciences Building, McGill University, Montreal, Quebec H3G 1Y6, Canada

Received for publication, February 3, 2005 , and in revised form, June 8, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
BAP31, a resident integral protein of the endoplasmic reticulum membrane, regulates the export of other integral membrane proteins to the downstream secretory pathway. Here we show that cell surface expression of the tetraspanins CD9 and CD81 is compromised in mouse cells from which the Bap31 gene has been deleted. CD9 and CD81 facilitate the function of multiprotein complexes at the plasma membrane, including integrins. Of note, BAP31 does not appear to influence the egress of {alpha}5{beta}1 or {alpha}v{beta}3 integrins to the cell surface, but in Bap31-null mouse cells, these integrins are not able to maintain cellular adhesion to the extracellular matrix in the presence of reduced serum. Consequently, Bap31-null cells are sensitive to serum starvation-induced apoptosis. Reconstitution of wild-type BAP31 into these Bap31-null cells restores integrin-mediated cell attachment and cell survival after serum stress, whereas interference with the functions of CD9, {alpha}5{beta}1, or {alpha}v{beta}3 by antagonizing antibodies makes BAP31 cells act similar to Bap31-null cells in these respects. Finally, in human KB epithelial cells protected from apoptosis by BCL-2, the caspase-8 cleavage product, p20 BAP31, inhibits egress of tetraspanin and integrin-mediated cell attachment. Thus, p20 BAP31 can operate upstream of BCL-2 in living cells to influence cell surface properties due to its effects on protein egress from the endoplasmic reticulum.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
BAP31 is an evolutionarily conserved polytopic integral protein of the endoplasmic reticulum (ER)1 membrane implicated in regulating the export of selected membrane proteins from the ER to downstream compartments of the secretory pathway. It forms part of a large BAP hetero-oligomeric complex (1–5). Examples of newly synthesized integral membrane proteins in the ER with which the BAP proteins associate and regulate their egress from the organelle include mIgD (5), cellubrevin (6), major histocompatibility complex class I (7, 8), and cystic fibrosis transmembrane conductance regulator (9). Additionally, BAP31 has been shown to regulate the turnover of the resident ER integral membrane protein tyrosine phosphatase-like B and, therefore, may also have a quality control function (10). BAP31 is emerging, therefore, as a putative chaperone/quality control factor that regulates the fate of integral membrane proteins in the ER membrane. Because BAP31 has also been shown to be an important target of caspases in certain apoptosis pathways (2, 11–15), inactivation of this protein might be expected to influence a variety of cellular functions.

Regulation of the transport of newly synthesized integral membrane proteins of the ER has important implications for maintaining the integrity of many cell surface functions, and defects in this process are well known to contribute to numerous diseases (16, 17). In this study, we have investigated the role of BAP31 in maintaining the cell surface expression of small integral membrane proteins called tetraspanins, which are implicated in the regulation of diverse plasma membrane activities. Tetraspanins comprise a large 4-spanning transmembrane super family (TM4SF) of proteins, which have been conserved throughout evolution, are ubiquitously expressed, and include the differentiation antigens CD9, CD81, CD82, and CD151 (18). Tetraspanins have been functionally implicated in different cellular processes, including cell adhesion, migration, cell signaling, metastasis, and growth (18–21). They act as molecular adaptors or facilitators and associate with large cell surface-signaling complexes to form the "tetraspanin web" (18, 22, 23,). Among the functions dependent on tetraspanins are those associated with several integrins ({alpha}5{beta}1, {alpha}4{beta}1, {alpha}3{beta}1, {alpha}6{beta}1) (20, 22, 24–26), major histocompatibility complex class I and II molecules (27), co-receptors (e.g. CD4 and CD8 antigens on T cells) (28), and other tetraspanins (22). In addition, some TM4SF proteins associate with intracellular signaling molecules on the cytoplasmic side of the plasma membrane, including tyrosine phosphatases (29), phosphatidylinositol 4-kinase (30), and small GTP-binding proteins (31).

Two TM4SF proteins, CD9 and CD81, have been implicated in the maintenance of functional integrins at the cell surface (20, 24, 26), transmembrane receptors that function in cell adhesion, migration, proliferation, differentiation, and survival (32, 33). The integrin family comprises non-covalent heterodimers of different type I transmembrane protein subunits called {alpha} and {beta}, which facilitate cell adhesion to extracellular matrix (ECM) substrates, including fibronectin ({alpha}5{beta}1 and {alpha}4{beta}1), laminin ({alpha}3{beta}1), and collagens ({alpha}2{beta}1) (33, 34). The ability of integrins to decrease or increase binding of cells to ECM ligands depends on the transition between inactive and active conformations of these receptors (35). Cellular factors known to induce the activation of integrins include inside-out signaling pathways, integrin clustering, the concentration of Mg2+ and Mn2+ in the extracellular medium, and temperature (35–38). Additionally, specific "activating" and "antagonizing" monoclonal antibodies have been generated that induce a high affinity/avidity conformational change upon binding to particular integrin epitopes (39, 40). Moreover, the activation state of integrins, including {alpha}5{beta}1, can be monitored by monoclonal antibodies that recognize conformation-dependent integrin epitopes that become exposed only upon changes in integrin conformations associated with changes in the affinity/avidity for ligand (41, 42). Some members of the {beta}1 integrin subfamily, including {alpha}5{beta}1 (VLA-5), have been found associated with CD9 and CD81 in the tetraspanin web (20, 24, 43). Consistent with this, CD81 has also been implicated in the regulation of {alpha}5{beta}1 adhesion strengthening in monocytes and primary mouse B cells (20). Tetraspanins can both increase and decrease {beta}1 integrin-mediated cell adhesion when challenged with specific monoclonal antibodies against tetraspanins (20, 44–46). Moreover, tetraspanins contribute to adhesion-dependent signaling by stimulating recruitment of signaling molecules, such as protein kinase C and phosphoinositide 3-kinase, into integrin complexes on the cytoplasmic side of the plasma membrane (47, 48). Changes in integrin-mediated signaling in response to serum starvation, for example, interferes with integrin-transduced survival pathways, alters cytoskeletal organization, and induces a form of programmed cell death called anoikis (49). Cells with non-functional or improperly activated integrins are more susceptible to anoikis (30, 50).

Here we show by gene deletion that BAP31 controls the egress of tetraspanins CD9 and CD81 to the cell surface and, in so doing, indirectly regulates integrin-mediated cell attachment and survival. In the Fas death pathway, BAP31 is a target of caspase-8, generating p20 BAP31, which induces a pro-apoptotic ER-mitochondrial pathway inhibited by pro-survival BCL-2 (2, 14). Of note, p20 BAP31 can also operate upstream of BCL-2 in BCL-2-protected living cells to inhibit egress of tetraspanin to the cell surface and compromise integrin-mediated cell attachment. This novel finding argues that the caspase cleavage product of BAP31 can regulate important cell surface events in cells protected from cell death.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
 REFERENCES
 
Cell Culture, Antibodies, Reagents, and Viral Infection—A C57BL/6 mouse embryonic stem cell line was generated following deletion of the Bap31 gene by homologous recombination and differentiated into epithelial-like cells (13). The cells were reconstituted with plasmid stably expressing either neomycin (Bap31-null) or BAP31-FLAG (10) and the cell lines maintained at 37 °C and 5% CO2 in KNOCKOUTTM Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 15% FBS, 1 mM minimal essential medium, nonessential amino acids, 2 mM L-glutamine, 100 units/ml streptomycin sulfate and penicillin, and 1 mM {beta}-mercaptoethanol. KB epithelial cells stably expressing BCL-2 (Bcl-2 cells) have been described previously (51). The following antibodies were used in this study: chicken or rabbit anti-human BAP31 (10); rat anti-mouse CD9 (clone KMC8) (Research Diagnostics, Inc.); hamster anti-mouse CD81/TAPA1 (clone EAT2) (eBioscience); mouse anti-{beta} actin (clone C4) (ICN Pharmaceuticals); rabbit anti-{gamma}-actin (2); hamster anti-mouse CD51 (integrin {alpha}v, clone H9.2B8) (BD Biosciences); rat anti-mouse CD49e (integrin {alpha}5, clone 5H10–27) (BD Biosciences); rabbit anti-mouse CD49e (clone H-104) (Santa Cruz Biothechnology); goat anti-mouse CD29 (integrin {beta}1, clone N-20) (Santa Cruz Biotechnology); hamster anti-mouse CD49b (integrin {alpha}2, clone Ha1/29) (BD Biosciences); hamster anti-mouse CD61 (integrin {beta}3, clone 2C9.G2) (BD Biosciences); mouse anti-p130CAS (BD Transduction Laboratories); 0.1% solution Fibronectin (Sigma). The construction of Adp20 and AdrtTa and all viral infections were conducted as described previously (14).

FACS Analysis—To assess the cell surface levels of specific tetraspanins and integrins in the presence or absence of BAP31, Bap31-null/Neo and Bap31-null/BAP31-FLAG cells were removed from plates by trypsinization and incubated on ice for 30 min in 50 µl of FACS buffer (PBS with 1% bovine serum albumin and 0.01% NaN3) containing 1.5 µg of specific primary antibodies, either against tetraspanins or integrins. The cells were washed three times with FACS buffer and labeled with a species-specific fluorescein isothiocyanate-conjugated antibody for 30 min on ice. After washing, the cells were analyzed by flow cytometry using a BD Biosciences FACSCalibur system.



View larger version (45K):
[in this window]
[in a new window]
  		FIG. 1.
Presence of BAP31 promotes cell surface expression levels of CD81 and CD9. A, equivalent samples of cell lysates from Bap31-null and Bap31-null/BAP31 murine embryonic stem cell lines were analyzed by immunoblotting with anti-BAP31 and anti-{gamma}-actin antibodies. B, detection of total endogenous CD81 and CD9 in Bap31-null and Bap31-null/BAP31 cells by immunoblotting of total lysed cell extracts with anti-mouse CD81 (EAT2) or anti-mouse CD9 (KMC8), with equal loading confirmed using anti-{gamma}-actin. C, cell surface expression of CD81 and CD9 detected by flow cytometry of intact Bap31-null or Bap31-null/BAP31 cells stained with anti-mouse CD81 (EAT2) or anti-mouse CD9 (KMC8). The graph represents the average of five independent experiments (Counts = relative fluorescence intensity). D, cellular localization of CD9 detected by immunofluorescence of intact Bap31-null and Bap31-null/BAP31 cells stained with anti-mouse CD9 (KMC8).

 
Fluorescence Microscopy—Cells were seeded at 60% confluency on glass coverslips, and then 24 h later were washed in PBS and fixed in 4% paraformaldehyde, 23 mM NaH2PO4, and 77 mM Na2HPO4, pH 7.3. Cells were permeabilized in PBS/0.2% Triton X-100 and then incubated in blocking buffer (10% fetal calf serum and 0.1% Triton X-100 in PBS). Primary and secondary antibody incubations were done in blocking buffer for 1 h each at room temperature using the indicated antibody and goat anti-mouse IgG secondary antibody coupled to Alexa 488 (green) (Molecular Probes, Inc.). The cells were visualized by conventional fluorescence microscopy using an inverted microscope (TE-FM Epi-fl, Nikon).

Purification of ECM and Cell Adhesion Assays—The ECM secreted by the BL6 parental cell line was extracted as follows: 1 x 104 cells/cm2 were seeded in 24-well tissue culture plates and cultured for 4 days. Confluent cultures were washed twice with cold PBS, incubated for 10 min with 0.5% Triton X-100 in PBS on ice to remove cell membranes, and another 10 min with 0.25 mM ammonium acetate to remove remaining nuclei and cytoskeleton. The remaining ECM was washed twice with ice-cold PBS and incubated overnight with a solution of 1% bovine serum albumin at 4 °C to cover exposed plastic surfaces. The ECM was washed once with serum-free medium before use in the adhesion assays. To measure cell-ECM adhesion, confluent Bap31-null/Neo and Bap31-null/BAP31-FLAG cell cultures were collected by light trypsinization, incubated at 37 °C in general medium for 1 h, washed three times with serum-free medium, and suspended at a concentration of 4 x 105cells/ml in serum-free medium. 0.25 ml/well of each cellular suspension was added to purified ECM, incubated for 1 h at 37 °C, and washed twice with PBS to remove unattached cells. The remaining attached cells were removed with trypsin and their number determined using a particle counter (Coulter Electronics Inc., Hialeah, FL). Adhesion to fibronectin was measured using 24-well plates coated with 10 µg/ml fibronectin or 2 mg/ml poly-L-lysine as a negative control (0.25 ml/well) by overnight incubation at 4 °C, followed by incubation for a minimum of 8 h at 4 °C with 1% bovine serum albumin, and subsequently washing with serum-free medium. The number of adherent cells was determined as described above for adhesion to purified ECM. For experiments with blocking antibodies, the cells were pre-incubated with 5 µg/ml purified antibodies on ice for 30 min, and adhesion assays were performed in the presence of antibodies.



View larger version (11K):
[in this window]
[in a new window]
  		FIG. 2.
BAP31 facilitates cell adhesion to fibronectin without affecting cell surface expression of integrins. A, Bap31-null (white bars) and Bap31-null/BAP31 cells (black bars) were cultured on plates coated with poly-L-lysine, ECM, or fibronectin (FN) under serum starvation conditions for 1 h, and the number of adherent cells was determined as described under "Experimental Procedures." Data from three independent experiments is presented as the mean ± S.D. B, quantification of cell surface expression of {alpha}2, {alpha}5, {alpha}V, {beta}3, and {beta}1 integrin subunits by flow cytometry of the equivalent number of BAP31-null (white bars) and Bap31-null/BAP31 (black bars) cells using anti-mouse {alpha}2 (Ha1/29), anti-mouse {alpha}5 (5H10–27), anti-mouse {alpha}V (H9.2B8), anti-mouse {beta}3 (2C9.G2), and anti-mouse {beta}1(N-20) antibodies. C, Bap31-null/BAP31 cells were incubated with 5 µg/ml either the control antibody {alpha}2 (Ha1/29) or blocking antibody to CD9 (KMC8), plated on fibronectin, and cultured in serum-starved conditions for 1 h. The number of attached cells was determined. The graph presents the mean results of three independent determinations ± S.D.

 



View larger version (22K):
[in this window]
[in a new window]
  		FIG. 3.
Treatment of Bap31-null/BAP31 cells with antibody against the {alpha}5 subunit of {alpha}5{beta}1 or the {alpha}V subunit of {alpha}V{beta}3 integrins inhibits adhesion to fibronectin (FN). Bap31-null and Bap31-null/BAP31 cells were incubated with 5 µg/ml blocking antibodies to {alpha}5{beta}1 (5H10–27) and {alpha}V{beta}3 (H9.2B8), plated on fibronectin, cultured in serum-starved conditions for 1 h, and the number of attached cells determined, as described under "Experimental Procedures." The graph presents the mean of three independent determinations ± S.D.

 
Immunoblotting—Confluent cells were lysed in 1% Triton X-100, 150 mM NaCl, 50 mM Hepes, 10% glycerol, and 1 mM EDTA) for 1 h at 4°C, and proteins were resolved by SDS-PAGE. After transferring to nitrocellulose membrane, proteins were probed with appropriate primary and secondary antibodies and visualized using ECL reagent (Amersham Biosciences).

Serum Starvation and Apoptotic Assays—Bap31-null/neo and Bap31-null/BAP31-FLAG cells were plated in 15% FBS KNOCKOUT Dulbecco's modified Eagle's medium, and 24 h later the cells were washed with PBS and cultured in 0.5% FBS KNOCKOUT Dulbecco's modified Eagle's medium. After 21 and 48 h of serum starvation, cell morphology was examined by phase-contrast microscopy. DEVD-aminomethyl coumarin caspase activity (Upstate Biothechnology, Lake Placid, NY) and Annexin V staining (BioVision, MountView, CA) were conducted according to the manufacturer's protocols. For experiments with blocking antibodies, serum starvation was performed in the presence of 5 µg/ml monoclonal antibodies.


   RESULTS AND DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
REFERENCES
 
Deletion of BAP31 Affects the Surface Expression of Tetraspanins CD81 and CD9 —To investigate the contribution of BAP31 to the cell surface expression of CD81 and CD9, we employed a differentiated C57BL/6 embryoid epithelial-like mouse cell line deleted of the Bap31 gene and stably transfected with plasmid expressing either neo (Bap31-null) or wild-type BAP31-FLAG (Bap31-null/BAP31) (10) (Fig. 1A). For the cell line expressing the wild-type BAP31-FLAG put-back, the expression level of the BAP31-FLAG was similar to the level of Bap31 found in parental C57BL/6 cells. Bap31-null cells were found to express total cellular CD81 and CD9 at levels similar to that of Bap31-null/BAP31 cells, as judged by immunoblotting (Fig. 1B). In contrast, FACS analysis using anti-CD9 and anti-CD81 indicated a significant reduction in the cell surface levels of these proteins in cells lacking Bap31 (Fig. 1C). Consistent with the FACS analysis, immunofluorescence microscopy showed that CD9 was enriched and punctuated at the cell surface in Bap31-null/BAP31 cells, but in Bap31-null cells, it was enriched in a perinuclear region of the cell (Fig. 1D). The CD81 antibody was not adequate for this analysis. The results indicate, therefore, that BAP31 does not influence the total amount of CD9 and CD81 expressed by these cells but that BAP31 is required to maintain expression of CD9 and CD81 at the cell surface.



View larger version (65K):
[in this window]
[in a new window]
  		FIG. 4.
Deletion of Bap31 sensitizes cells to serum starvation-induced cell death. A, morphologies of the Bap31-null and Bap31-null/BAP31 cells were examined by phase-contrast microscopy following 21 and 42 h of culture under serum starvation conditions (0.5% FBS). B, cells were cultured for 0 and 42 h following exposure to reduced serum (0.5% FBS) and DEVDase activity determined by incubating cell lysates (normalized to equivalent protein) with DEVD-aminomethylcoumarin. Shown are the means ± S.D. from three independent determinations. C, cells were exposed to 0- or 48-h 0.5% FBS, stained with annexin V, and the fluorescence intensity determined by FACS analysis (Counts = relative fluorescence intensity).

 
BAP31 Promotes Cell Adhesion to Fibronectin without Affecting Cell Surface Expression of {alpha}5{beta}1 and {alpha}v{beta}3 Integrins—In view of the fact that CD9 and CD81 are adaptors that influence the activation status of select integrins at the cell surface, we surveyed the Bap31- and Bap31-null/BAP31 cells for their ability to manifest integrin-mediated properties, including attachment to the ECM. To that end, cell culture plates were coated with purified ECM or fibronectin (the component of the ECM that is recognized by {alpha}5{beta}1 and {alpha}v{beta}3 integrins). As documented in Fig. 2A, Bap31-null/BAP31 cells displayed a significantly higher cell binding to both ECM and fibronectin compared with Bap31-null cells, whereas the two cell lines bound equally well to poly-L-lysine-coated plates. In contrast to CD9 and CD81, however, overall expression of the two main fibronectin integrin receptors at the cell surface, {alpha}5{beta}1 and {alpha}v{beta}3, was not significantly different in either cell line, as demonstrated by flow cytometry; if anything, Bap31-null cells expressed slightly more {alpha}5 subunit than did Bap31-null/BAP31 cells (Fig. 2B). Thus, the absence of BAP31 decreases cell adhesion to ECM and fibronectin with no apparent effect on the cell surface expression of {alpha}5{beta}1 and {alpha}v{beta}3 integrins.

Blocking Cell Surface CD9 Inhibits Attachment of Bap31-null/BAP31 Cells to Fibronectin—To examine the possibility that the reduction in cell attachment to fibronectin in the absence of BAP31 expression was because of the reduced expression of tetraspanin at the surface of these cells, we explored the use of antibodies known to interfere with the function of tetraspanin. Only one antibody was identified that binds and functionally neutralizes certain CD9 functions in mouse (52). When added to Bap31-null/BAP31 cells, this anti-CD9 antibody reduced the binding of these cells to fibronectin, whereas a control antibody (anti-{alpha}2) did not (Fig. 2C). Anti-CD9, therefore, recapitulated the reduction in the integrin-mediated cell attachment that was observed due to targeted deletion of Bap31, suggesting that BAP31 maintains integrin function by promoting tetraspanin expression at the cell surface.

BAP31 Promotes Cell Attachment by Maintaining Integrin Activity—The Bap31-null and Bap31-null/BAP31 cells are differentiated epithelial-like cells, and epithelial cells are known to require {alpha}5{beta}1 and/or {alpha}v{beta}3 for their attachment to fibronectin (20, 53). To further confirm that these integrins were functional in BAP31-expressing cells, treatment of cells with integrin-blocking antibodies, which bind to the activated conformers of {alpha}5{beta}1 or {alpha}v{beta}3 integrins and inhibit their interactions with the ECM (53), were examined. Indeed, when Bap31-null/BAP31 cells were plated on fibronectin in the presence of inhibiting antibody to either {alpha}5 and {alpha}v integrin subunits, cell adhesion was decreased by half (Fig. 3). Thus, BAP31 maintains integrin activation to facilitate cell attachment to ECM. The fact that anti-{alpha}5 antibody also retarded the residual binding of Bap31-null cells to fibronectin suggests that inhibition of {alpha}5{beta}1 function following deletion of Bap31 was not absolute.

BAP31-expressing Cells Resist Apoptosis Triggered by Serum Deprivation—Many types of cells, including epithelial cells, require appropriate cell-ECM interactions for survival, and they undergo apoptosis in response to stimuli, such as serum depletion, when these anchorage-dependent interactions are lost (54, 55). Our finding that BAP31 is required to maintain integrin activity at the cell surface suggests that BAP31 should also confer resistance to serum starvation-induced cell death. This was tested by plating Bap31-null and Bap31-null/BAP31 cells in serum-reduced medium and examining their morphology by light microscopy. Bap31-null cells displayed typical apoptotic morphological changes, such as cell rounding, condensation, and detachment, whereas the majority of Bap31-null/BAP31 cells remained attached and well spread even after 42 h of serum starvation (Fig. 4A). In addition to changes in cell morphology, Bap31-null cells (but not Bap31-null/BAP31 cells) displayed a strong induction of effector caspase (DEVDase) activity after 42 h of exposure to low serum (Fig. 4B), which was the time at which maximal DEVDase activity was observed (not shown). This was associated with loss of plasma membrane asymmetry, as demonstrated by annexin V staining (Fig. 4C). The results demonstrated that Bap31-null cells are susceptible to apoptosis in response to serum deprivation and that reconstitution of wild-type BAP31 in these cells maintains resistance to this apoptotic stimulus.

Bap31-null/BAP31 Cells Die in Response to Serum Deprivation after Functional Inhibition of Integrins—To confirm that cell surface expression of {alpha}5{beta}1 and/or {alpha}v{beta}3 in Bap31-null/BAP31 cells confers resistance to serum starvation-induced cell death, we investigated this stress response in Bap31-null/BAP31 cells in either the presence or the absence of antibodies against {alpha}5 and {alpha}V, which are known to antagonize the function of the respective integrin. The cells were cultured in medium containing 0.5% FBS without (control) or with blocking antibodies, and the samples were analyzed after 0 and 48 h. Induction of apoptosis was monitored by the appearance of DEVDase activity. As shown in Fig. 5, serum withdrawal induced DEV-Dase activity only in Bap31-null/BAP31 cells treated with blocking antibodies to {alpha}5 or {alpha}V. Thus, interference with functional {alpha}5{beta}1 or {alpha}v{beta}3 in cells expressing wild-type BAP31 recapitulated the sensitivity of Bap31-null cells to serum starvation, arguing that maintenance of functional cell surface integrins by BAP31 confers cell survival in response to serum deprivation.

The Caspase-8 Cleavage Product of BAP31 Inhibits Egress of CD9 to the Cell Surface in Human Epithelial Cells Protected by BCL-2—BAP31 is cleaved by caspase-8 following activation of the Fas death pathway upstream of the BCL-2-regulated mitochondrial apoptosis pathway (2, 4, 11, 14) (Fig. 6A). The resulting p20 BAP31 product remains at the ER where it strongly interacts with full-length, uncleaved BAP31 and, independently of this association, initiates a BCL-2-inhibitable pathway that results in mitochondrial fragmentation and sensitization of the organelle to other pro-apoptotic stimuli (4, 14). To determine whether the caspase cleavage product of BAP31 influences egress of tetraspanins to the cell surface independently of other potential changes caused by Fas stimulation, p20 BAP31 was ectopically expressed in human KB epithelial cells employing an adenovirus vector (14) (Fig. 6B). To prevent p20-induced mitochondrial apoptosis, these cells also stably overexpressed BCL-2 (51). At 24 h post-infection with Adp20, the caspase-3/7 target p130Cas remained intact (Fig. 6B), and <5% of these p20-expressing cells were scored as apoptotic (Fig. 6D). FACS analysis of the cells revealed, however, that, compared with control adenovirus vector (Ad rTta), p20 BAP31 had indeed interfered with expression of CD9 at the cell surface (Fig. 6C). Similar analyses of CD81 were not conducted because of the quality of the antibody recognizing the human protein. Consequently, Adp20 caused a reduction in cell attachment to fibronectin (Fig. 6E). Because these cells also expressed full-length BAP31 (Fig. 6B), the results clearly showed that the p20 cleavage product is a dominant-interfering protein that compromises the ability of BAP31 to maintain cell surface expression of tetraspanin.



View larger version (13K):
[in this window]
[in a new window]
  		FIG. 5.
BAP31-expressing cells are sensitized to induction of apoptosis under serum starvation conditions by antagonizing antibodies to integrin {alpha}5 or {alpha}V subunits. Cells were incubated without (Ctrl) or with 5 µg/ml either anti-mouse {alpha}5 (5H10–27) or anti-mouse {alpha}V (H9.2B8), plated on 6-well dishes in low serum medium for 48 h, and cell lysates (equivalent protein) analyzed for DEVDase activity. Shown are the means ± S.D. from three independent determinations.

 
In conclusion, we have provided evidence that, similar to mIgD (5), cystic fibrosis transmembrane conductance regulator (9), and major histocompatibility complex class I (7, 8), cell surface expression of the tetraspanins CD9 and CD81 is regulated by BAP31, a resident chaperone located in the ER membrane. As shown here, loss of BAP31 function, although not lethal to differentiated epithelial-like mouse embryonic stem cells, does have predictable outcomes in terms of influencing complex pathways that are expressed at the cell surface. Although loss of BAP31 did not manifest in transport defects of {alpha}5{beta}1 or {alpha}v{beta}3 integrins to the cell surface, for example, the compromised transport of CD9 and CD81 tetraspanins indirectly affected the functional integrity of these integrins. As a result, loss of BAP31 correlated with increased sensitivity to the induction of apoptosis by serum starvation. An additional outcome of these findings is the fact that BAP31 exhibits selectivity for the transmembrane proteins which egress out of the ER it supports. Interrogating differences between BAP31-dependent and -independent mechanisms will be important to better understand the export of newly synthesized integral membrane proteins.



View larger version (24K):
[in this window]
[in a new window]
  		FIG. 6.
The p20 caspase cleavage product of BAP31 lowers cell surface expression levels of CD9 and inhibits adhesion to fibronectin in the absence of apoptosis. A, schematic of BAP31 cleavage by caspase-8; the overlapping death effector-like, coiled-coil domain is designated as DECC, and the caspase cleavage sites indicated by asterisks (2, 4, 11). B, expression of Adp20 in human KB epithelial cells stably overexpressing BCL-2 (BCL-2 cells) (58) does not induce the cleavage of Bap31 or p130CAS. Untreated or cells infected with either Adp20 or AdrtTa (control) were collected, and equivalent samples of cell lysates were analyzed by immunoblotting at 24 h post-infection with anti-BAP31, anti-p130CAS, and anti-actin antibodies. C, cell surface expression of CD9 detected by flow cytometry of BCL-2 cells, infected either with Adp20 or AdrtTa for 24 h, stained with anti-mouse CD9 (KMC8). The graph represents the average of three independent experiments (Counts = relative fluorescence intensity). D, BCL-2 cells were infected either with Adp20 or AdrtTa, and at 24 h post infection, the percent of apoptotic cells was assessed by trypan blue uptake and staining. E, the indicated cells were cultured on plates coated with fibronectin under serum starvation conditions for 1 h, and the number of adherent cells was determined as described under "Experimental Procedures." The graphs present the mean results of three independent determinations ± S.D.

 
Importantly, BAP31 itself is a target of regulation during the cellular response to death receptor stimulation (2, 4). Activation of caspase-8 is a proximal event following death receptor stimulation and results in cleavage of BAP31 upstream of the mitochondrial death pathway, destroying its ability to resist Fas-mediated cell death (2, 4, 11). Conversely, the cleavage product is pro-apoptotic and induces a rapid release of ER Ca2+, initiating a pathway that sensitizes mitochondria to apoptotic stimuli (11, 14). In type II epithelial cells, overexpression of BCL-2 prevents cell death induced by Fas stimulation, because the mitochondrial death pathway and ER Ca2+-release are blocked (14, 56). What we have demonstrated here, however, is that upstream generation of p20 BAP31 by activated caspase-8 in living cells overexpressing BCL-2 could influence the integrity of cell surface functions, including integrin-mediated attachment to extracellular matrices.

BAP31 is emerging as an important regulator of the egress of a subset of newly synthesized integral membrane proteins out of the ER, which includes quality control (5, 10), export receptor (7, 8, 57), and perhaps chaperone functions. It is part of a large oligomeric structure (5), but it is not yet clear how this structure operates. Following caspase cleavage of BAP31, it loses its association with actomyosin (2, 3). This, together with potential influences of caspase cleavage on the large BAP31 complex itself, could contribute to the resulting inhibition of the role of BAP31 in supporting the transport of membrane proteins to the cell surface.


   FOOTNOTES
 
* This work was supported by the Canadian Institutes of Health Research and the National Cancer Institute of Canada through funds provided by the Canadian Cancer Society. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

§ Recipient of the Canadian Institutes of Health Research Doctoral Research award. Back

|| To whom correspondence should be addressed: Dept. of Biochemistry, McIntyre, Medical Sciences Bldg., McGill University, 3655 Promenade Sir William Osler, Montreal, Quebec H3G 1Y6, Canada. Tel.: 514-398-7282; Fax: 514-398-7384; E-mail: gordon.shore{at}mcgill.ca.

1 The abbreviations used are: ER, endoplasmic reticulum; ECM, extracellular matrix; FBS, fetal bovine serum; FACS, fluorescence-activated cell sorter; PBS, phosphate-buffered saline. Back


   ACKNOWLEDGMENTS
 
We thank Dr. Stanners for providing the antibodies to integrins {alpha}2 and {beta}3, as well as for helpful discussions.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 

  1. Adachi, T., W.W., Schimel, K.M,. Kim, T., Watanabe, B., Becker, P.J., Nielsen, and M. Reth. (1996) EMBO J. 15, 1534–1541[Medline] [Order article via Infotrieve]
  2. Nguyen, M., Breckenridge, D.G., Ducret, A., Shore, G.C. (2000) Mol. Cell. Biol. 20, 6731–6740[Abstract/Free Full Text]
  3. Ducret, A., Nguyen, M., Breckenridge, D.G., Shore, G.C. (2003) Eur. J. Biochem. 270, 342–349[Medline] [Order article via Infotrieve]
  4. Wang, B., Nguyen, M., Breckenridge, D.G., Stojanovic, M., Clemons, P.A., Kuppig, S., Shore, G.C. (2003) J. Biol. Chem. 278, 14461–14468[Abstract/Free Full Text]
  5. Schamel, W.W., Kuppig, S., Becker, B., Gimborn, K., Hauri, H.P., Reth, M. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 9861–9866[Abstract/Free Full Text]
  6. Annaert, W.G., Becker, B., Kistner, U., Reth, M., Jahn, R. (1997) J. Cell Biol. 139, 1397–1410[Abstract/Free Full Text]
  7. Spiliotis, E.T., Manley, H., Osorio, M., Zuniga, M.C., Edidin, M. (2000) Immunity 13, 841–851[CrossRef][Medline] [Order article via Infotrieve]
  8. Paquet, M.E., Cohen-Doyle, M., Shore, G.C., Williams, D.B. (2004) J. Immunol. 172, 7548–7555[Abstract/Free Full Text]
  9. Lambert, G., Becker, B., Schreiber, R., Boucherot, A., Reth, M., Kunzelmann, K. (2001) J. Biol. Chem. 276, 20340–20345[Abstract/Free Full Text]
  10. Wang, B., Pelletier, J., Massaad, M.J., Herscovics, A., Shore, G.C. (2004) Mol. Cell. Biol. 24, 2767–2778[Abstract/Free Full Text]
  11. Ng. F.W., Nguyen, M., Kwan, T., Branton, P.E., Nicholson, D.W., Cromlish, J.A., Shore, G.C. (1997) J. Cell Biol. 139, 327–338[Abstract/Free Full Text]
  12. Granville, D.J., Carthy, C.M., Jiang, H., Shore, G.C., McManus, B.M., Hunt, D.W. (1998) FEBS Lett. 437, 5–10[CrossRef][Medline] [Order article via Infotrieve]
  13. Breckenridge, D.G., Nguyen, M., Kuppig, S., Reth, M., Shore, G.C. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 4331–4336[Abstract/Free Full Text]
  14. Breckenridge, D.G., Stojanovic, M., Marcellus, R.C., Shore, G.C. (2003) J. Cell Biol. 160, 1115–1127[Abstract/Free Full Text]
  15. Chandra, D., Choy, G., Deng, X., Bhatia, B., Daniel, P., Tang, D.G. (2004) Mol. Cell. Biol. 24, 6592–6607[Abstract/Free Full Text]
  16. Amara, J.F., Cheng, S.H., Smith, A.E. (1992) Trends Cell Biol. 2, 145–149[CrossRef][Medline] [Order article via Infotrieve]
  17. Aridor, M., Hannan, L.A. (2000) Traffic 1, 836–851[CrossRef][Medline] [Order article via Infotrieve]
  18. Boucheix, C., Rubinstein, E. (2001) Cell Mol. Life Sci. 58, 1189–1205[CrossRef][Medline] [Order article via Infotrieve]
  19. Lagaudriere-Gesbert, C., Le Naour, F., Lebel-Binay, S., Billard, Lemichez, E., Boquet, P., Boucheix, C., Conjeaud, H., Rubinstein, E. (1997) Cell. Immunol. 182, 105–112[CrossRef][Medline] [Order article via Infotrieve]
  20. Feigelson, S.W., Grabovsky, V., Shamri, R., Levy, S., Alon, R. (2003) J. Biol. Chem. 278, 51203–51212[Abstract/Free Full Text]
  21. Hemler, M. E. (2001) J. Cell Biol. 155, 1103–1107[Abstract/Free Full Text]
  22. Rubinstein, E., Le Naour, F., Lagaudriere-Gesbert, C., Billard, M., Conjeaud, H., Boucheix, C. (1996) Eur. J. Immunol. 26, 2657–2665[Medline] [Order article via Infotrieve]
  23. Charrin. S., Manie, S., Billard, M., Ashman, L., Gerlier, D., Boucheix, C., Rubinstein, E. (2003) Biochem. Biophys. Res. Commun. 304, 107–112[CrossRef][Medline] [Order article via Infotrieve]
  24. Rubinstein, E., Le Naour, F., Billard, M., Prenant, M., Boucheix, C. (1994) Eur. J. Immunol. 24, 3005–3013[Medline] [Order article via Infotrieve]
  25. Serru, V., Le Naour, F., Billard, M., Azorsa, D.O., Lanza, F., Boucheix, C., Rubinstein, E. (1999) Biochem. J. 340, 103–111[CrossRef][Medline] [Order article via Infotrieve]
  26. Berditchevski, F., Odintsova, E. (1999) J. Cell Biol. 146, 477–492[Abstract/Free Full Text]
  27. Secrist, H., Levy, S., DeKruyff, R.H., Umetsu, D.T. (1996) Eur. J. Immunol. 26, 1435–1442[Medline] [Order article via Infotrieve]
  28. Imai, T., Yoshie, O. (1993) J. Immunol. 151, 6470–6481[Abstract]
  29. Carmo, A.M., Wright, M.D. (1995) Eur. J. Immunol. 25, 2090–2095[Medline] [Order article via Infotrieve]
  30. Yauch, R.L., Hemler, M.E. (2000) Biochem. J. 351, 629–637[CrossRef][Medline] [Order article via Infotrieve]
  31. Shigeta, M., Sanzen, N., Ozawa, M., Gu, J., Hasegawa, H., Sekiguchi, K. (2003) J. Cell Biol. 163, 165–176[Abstract/Free Full Text]
  32. Miranti, C.K., Brugge, J.S. (2002) Nat. Cell Biol. 4, E83–90[CrossRef][Medline] [Order article via Infotrieve]
  33. Berman, A.E., Kozlova, N.I., Morozevich, G.E. (2003) Biochemistry (Mosc).68, 1284–1299[CrossRef][Medline] [Order article via Infotrieve]
  34. Lussier, C., Basora, N., Bouatrouss, Y., Beaulieu, J.F. (2000) Microsc. Res. Tech. 51, 169–178[CrossRef][Medline] [Order article via Infotrieve]
  35. Hughes, P.E., Pfaff, M. (1998) Trends Cell Biol. 8, 359–364[CrossRef][Medline] [Order article via Infotrieve]
  36. Yauch, R.L., Felsenfeld, D.P., Kraeft, S.K., Chen, L.B., Sheetz, M.P., Hemler, M.E. (1997) J. Exp. Med. 186, 1347–1355[Abstract/Free Full Text]
  37. Mould, A.P., Askari, J.A., Barton, S., Kline, A.D., McEwan, P.A., Craig, S.E., Humphries, M.J. (2002) J. Biol. Chem. 277, 19800–19805[Abstract/Free Full Text]
  38. Sanchez-Mateos, P., Cabanas, C., Sanchez-Madrid, F. (1996) Semin. Cancer Biol. 7, 99–109[CrossRef][Medline] [Order article via Infotrieve]
  39. Clark, K., Pankov, R., Travis, M.A., Askari, J.A., Mould, A.P., Craig, S.E., Newham, P., Yamada, K.M., Humphries, M.J. (2004) J. Cell Sci. [Epub ahead of print]
  40. Mould, A.P., Travis, M.A., Barton, S.J., Hamilton, J.A., Askari, J.A., Craig, S.E., Macdonald, P.R., Kammerer, R.A., Buckley, P.A., Humphries, M.J. (2004) J. Biol. Chem. [Epub ahead of print]
  41. Tsuchida, J., Ueki, S., Takada, Y., Saito, Y., Takagi, J. (1998) J. Cell Sci. 111, 1759–1766[Abstract]
  42. Luque, A., Gomez, M., Puzon, W., Takada, Y., Sanchez-Madrid, F., Cabanas, C. (1996) J. Biol. Chem. 271, 11067–11075[Abstract/Free Full Text]
  43. Hirano, T., Higuchi, T., Ueda, M., Inoue, T., Kataoka, N., Maeda, M., Fujiwara, H., Fujii, S. (1999) Mol. Hum. Reprod. 5, 162–167[Abstract/Free Full Text]
  44. Cook, G.A., Longhurst, C.M., Grgurevich, S., Cholera, S., Crossno, JTQQPERIODJUNIORPERIODQQ, Jennings, L.K. (2002) Blood 100, 4502–4511[Abstract/Free Full Text]
  45. Gutierrez-Lopez, M.D., Ovalle, S., Yanez-Mo, M., Sanchez-Sanchez, N., Rubinstein, E., Olmo, N., Lizarbe, M.A., Sanchez-Madrid, F., Cabanas, C. (2003) J. Biol. Chem. 278, 208–218[Abstract/Free Full Text]
  46. Cook, G.A., Wilkinson, D.A., Crossno, J. T., Jr., Raghow, R., Jennings, L.K. (1999) Exp. Cell Res. 251, 356–371[CrossRef][Medline] [Order article via Infotrieve]
  47. Hemler, M. E. (1998) Curr. Opin. Cell Biol. 10, 578–585[CrossRef][Medline] [Order article via Infotrieve]
  48. Zhang, X.A., Bontrager, A.L., Hemler, M.E. (2001) J. Biol. Chem. 276, 25005–25013[Abstract/Free Full Text]
  49. Zhan, M., Zhao, H., Han, Z.C. (2004) Histol. Histopathol. 19, 973–983[Medline] [Order article via Infotrieve]
  50. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. (1994) Cell 79, 1157–1164[CrossRef][Medline] [Order article via Infotrieve]
  51. Nguyen, M., Branton, P.E., Roy, S., Nicholson, D.W., Alnemri, E.S., Yeh, W.C., Mak, T.W.
  52. Oritani, K., Wu, X., Medina, K., Hudson, J., Miyake, K., Gimble, J.M., Burstein, S.A., Kincade, P.W. (1996) Blood 87, 2252–2261[Abstract/Free Full Text]
  53. Schultz, J.F., Armant, D.R. (1995) J. Biol. Chem. 270, 11522–11531[Abstract/Free Full Text]
  54. Frisch, S.M., Francis, H. (1994) J. Cell Biol. 124, 619–626[Abstract/Free Full Text]
  55. Meredith, J. Jr., Fazeli, B., Schwartz, M.A. (1993) Mol. Biol. Cell 4, 953–961[Abstract]
  56. Breckenridge, D.G., Germain, M., Mathai, J.P., Nguyen, M., Shore, G.C. (2003) Oncogene 22, 8608–8618[CrossRef][Medline] [Order article via Infotrieve]
  57. Zen, K., Utech, M., Liu, Y., Soto, I., Nusrat, A., Parkos, C.A. (2004) J. Biol. Chem. 279, 44924–44930[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
J. A. Regan and L. A. Laimins
Bap31 Is a Novel Target of the Human Papillomavirus E5 Protein
J. Virol., October 15, 2008; 82(20): 10042 - 10051.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
Y. Wakana, S. Takai, K.-i. Nakajima, K. Tani, A. Yamamoto, P. Watson, D. J. Stephens, H.-P. Hauri, and M. Tagaya
Bap31 Is an Itinerant Protein That Moves between the Peripheral Endoplasmic Reticulum (ER) and a Juxtanuclear Compartment Related to ER-associated Degradation
Mol. Biol. Cell, May 1, 2008; 19(5): 1825 - 1836.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. J. Ladasky, S. Boyle, M. Seth, H. Li, T. Pentcheva, F. Abe, S. J. Steinberg, and M. Edidin
Bap31 Enhances the Endoplasmic Reticulum Export and Quality Control of Human Class I MHC Molecules
J. Immunol., November 1, 2006; 177(9): 6172 - 6181.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Szczesna-Skorupa and B. Kemper
BAP31 Is Involved in the Retention of Cytochrome P450 2C2 in the Endoplasmic Reticulum
J. Biol. Chem., February 17, 2006; 281(7): 4142 - 4148.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/34/30018    most recent
M501306200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stojanovic, M.
Right arrow Articles by Shore, G. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stojanovic, M.
Right arrow Articles by Shore, G. C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement